Glenmark ties up with Evestra to develop contraceptive
The companies will file for product approval in FY19
)
Explore Business Standard
Associate Sponsors
The companies will file for product approval in FY19
)
Glenmark Pharmaceuticals has tied up with Evestra Inc to develop and market a generic version of Merck's female contraceptive product. The companies will file for product approval in financial 2019.
Under the agreement, Evestra will develop generic version of NuvaRing exclusively for Glenmark for the US market and will receive certain milestone payments during various stages of its development, including royalties on net sales, Glenmark said.
"The partnership with Evestra. expands our portfolio into a leading non-daily contraceptive option prescribed for millions of women in the US," Glenmark's North America and Global API President Robert Matsuk said.
Already subscribed? Log in
Subscribe to read the full story →
3 Months
₹300/Month
1 Year
₹225/Month
2 Years
₹162/Month
Renews automatically, cancel anytime
Over 30 premium stories daily, handpicked by our editors


News, Games, Cooking, Audio, Wirecutter & The Athletic
Digital replica of our daily newspaper — with options to read, save, and share


Insights on markets, finance, politics, tech, and more delivered to your inbox
In-depth market analysis & insights with access to The Smart Investor


Repository of articles and publications dating back to 1997
Uninterrupted reading experience with no advertisements


Access Business Standard across devices — mobile, tablet, or PC, via web or app
First Published: Mar 02 2017 | 6:04 PM IST